MDM2 protein expression is a negative prognostic marker in breast carcinoma

• Published in: Modern pathology Vol. 19; no. 1; pp. 69 - 74
• Main Authors: Turbin, Dmitry A, Cheang, Maggie C U, Bajdik, Chris D, Gelmon, Karen A, Yorida, Erika, De Luca, Alessandro, Nielsen, Torsten O, Huntsman, David G, Gilks, C Blake
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2006; Elsevier Limited
• Subjects: Biomarkers; Biomarkers, Tumor - analysis; Breast cancer; breast carcinoma; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cyclin E - analysis; Female; Gene amplification; Humans; Immunohistochemistry - methods; Immunohistochemistry - statistics & numerical data; Keratin-5; Keratin-6; Keratins - analysis; Ki-67 Antigen - analysis; MDM2 protein; Pathology; Prognosis; Proportional Hazards Models; Protein expression; Proteins; Proto-Oncogene Proteins c-mdm2 - biosynthesis; Receptor, ErbB-2 - analysis; Receptors, Estrogen - analysis; Reproducibility of Results; Survival Analysis; Tissue Array Analysis - methods; Tissue Array Analysis - statistics & numerical data; tissue microarrays; Tumor Suppressor Protein p53 - analysis; Tumors; British Columbia Canada; Canada; tissue microarrays; MDM2 protein; survival analysis; breast carcinoma

The protein encoded by the MDM2 oncogene inhibits the function of p53, leading to increased cell growth, avoidance of apoptosis, tolerance of genetic instability, and resistance to chemotherapy. The present study was performed to evaluate the relationship between MDM2 protein expression and survival...